ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG (FRA:EUZ) EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
Transparency directive : regulatory news
22/03/2024 07:45
EQS-News: Eckert & Ziegler SE
/ Key word(s): Annual Results
Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
22.03.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, March 22, 2024 - Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.
In the Medical segment, sales rose by € 24.3 million or 27% to € 115.2 million compared to the previous year. The increase in sales was driven in particular by strong demand for radiopharmaceuticals. At € 130.9 million, sales in the Isotope Products segment remained at the previous year's level (€ 131.4 million).
For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT before special items from continuing operations of around € 50 million.
The full 2023 financial statements can be found here: https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz23e.pdf
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.
For enquiries please contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
22.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
Eckert & Ziegler SE |
|
Robert-Rössle-Str.10 |
|
13125 Berlin |
|
Germany |
Phone: |
+49 30 941084-138 |
Fax: |
+49 30 941084-0 |
Internet: |
www.ezag.de |
ISIN: |
DE0005659700 |
WKN: |
565970 |
Indices: |
SDAX, TecDax, |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1864787 |
|
End of News |
EQS News Service |
1864787 22.03.2024 CET/CEST